<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Cummings</title>
	<atom:link href="http://www.tapanray.in/tag/cummings/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Does Drug Pricing Freedom Benefit Patients in A Free-Market Economy?</title>
		<link>http://www.tapanray.in/does-drug-pricing-freedom-benefit-patients-in-a-free-market-economy/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=does-drug-pricing-freedom-benefit-patients-in-a-free-market-economy</link>
		<comments>http://www.tapanray.in/does-drug-pricing-freedom-benefit-patients-in-a-free-market-economy/#comments</comments>
		<pubDate>Mon, 13 Oct 2014 00:00:40 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[(NCPA)]]></category>
		<category><![CDATA[Committee on Oversight and Government Reform]]></category>
		<category><![CDATA[competition]]></category>
		<category><![CDATA[Cummings]]></category>
		<category><![CDATA[DPCO]]></category>
		<category><![CDATA[Dr. Reddy’s Laboratories]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[free-market]]></category>
		<category><![CDATA[freedom]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Myth]]></category>
		<category><![CDATA[National Community Pharmacists Association]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Senator Bernard Sanders]]></category>
		<category><![CDATA[Sun Pharma]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[update]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[Zydus Cadila]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6094</guid>
		<description><![CDATA[A 2010 USFDA update titled ‘Generic Competition and Drug Prices’ highlighted that generic competition is intimately associated with lower drug prices, and the entry of the second generic competitor is associated with the largest price reduction. The agency found that &#8230; <a href="http://www.tapanray.in/does-drug-pricing-freedom-benefit-patients-in-a-free-market-economy/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/does-drug-pricing-freedom-benefit-patients-in-a-free-market-economy/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
